Literature DB >> 6090353

Analysis of S-35 labeled WR-2721 and its metabolites in biological fluids.

K W Anderson, K A Krohn, Z Grunbaum, R B Phillips, P A Mahler, T W Menard, A M Spence, J S Rasey.   

Abstract

Studies with WR-2721 and related compounds have been hindered by the lack of a suitable assay for the drug and its major metabolites. We have developed a chromatographic method which requires no derivatization for the separation and detection of WR-2721, the free thiol, its symmetrical disulfide and other mixed disulfides. Our procedure involves ion-pairing for separation of ionizable compounds by causing polar molecules to become more lipophilic and hence separable using reverse phase HPLC. Detection is based upon liquid scintillation counting of S-35 incorporated during the synthesis of the parent compound. This method requires no pre-column preparation of samples and, by detecting the S-35 label, eliminates the chance that a coeluting species could interfere with detection, as might occur with post-column derivatization. Chromatography was done using a 10 micron C8RP column and 35% MeOH/65% 0.0113M NaH2PO4, 0.005 M hexanesulfonate, pH 5.9, flowing at 1 ml/min. Half-minute fractions were collected into scintillation vials for counting. Retention volumes for the various compounds were: column breakthrough (3.5 ml), WR-2721 (4.5 ml), WR-1065 (9 ml), and WR-33278 (24 ml). This analytical technique employing radiotracers can be used to study radioprotective mechanisms by time dependent measurements of the tissue distribution and chemical form of labeled drug. Such chemical information can then be correlated with biological measures of radiation protection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090353     DOI: 10.1016/0360-3016(84)90492-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  1 in total

1.  Development and Validation of an HPLC Method for Determination of Amifostine and/or Its Metabolite (WR-1065) In Human Plasma Using OPA Derivatization and UV Detection.

Authors:  Nasim Samiei; Seyed Mohsen Foroutan; Alireza Shafaati; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.